A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
PhasePhase 3
TypeInterventional
Age18 Years – 85 Years
WhereBirmingham, Alabama, United States + 66 more
SponsorCybin IRL Limited
▾Tap for detailsClick for full details — eligibility, all locations, contacts
67 sitesApply